The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Arnon NaglerThe GvHD Hub are proud to present expert interviews directly from the 61st American Society of Hematology (ASH) meeting in Orlando, US. This interview with Arnon Nagler, Tel Aviv University, Tel Aviv, IL, was based on the question: How do you select the optimal donor for transplant?
Professor Nagler discusses the difficulties that can be faced in finding a matched donor, and notes that haploidentical transplant from a parent, sibling or child is more prominent but less successful. However, new technology, especially non-T-cell depleted transplant with GvHD prophylaxis now can yield good results with almost no difference observed between matched-unrelated and haploidentical donors.
Professor Nagler concludes that sibling donors are the optimal donor where possible, though if there is insufficient time to search for an unrelated donor, then non-T-cell depleted haploidentical transplant with post-transplant cyclophosphamide should be conducted.
How do you select the optimal donor for transplant?